FORE Biotherapeutics Secures $67.4 Million in Series D-2 Extension Funding
FORE Biotherapeutics, a Philadelphia-based company specializing in the development of targeted cancer therapies, announced on July 8, 2026, that it has successfully raised $67.4 million in a Series D-2 Extension funding round. This round was led by SR One, Medicxi, and SymBiosis, with participation from a diverse group of investors including TaiAx, LG Technology Ventures, Primer Ventures Axil, OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Capital, Novartis Venture Fund, Windham Life Science Partners, Samsung, and 3B Capital.
Leadership at FORE Biotherapeutics
The company is helmed by founder and CEO Michael Vidne, alongside Chief Executive Officer William Hinshaw. Together, they lead the charge in advancing innovative solutions for cancer treatment. "This funding enables us to accelerate our clinical programs and expand our research capabilities," Vidne stated, emphasizing the strategic importance of this capital infusion.
Strategic Use of Funds
FORE Biotherapeutics plans to utilize the newly acquired funds to further its research and development efforts, particularly focusing on clinical trials and the expansion of its therapeutic pipeline. The company aims to advance its existing cancer treatment solutions and explore new avenues in oncology that could benefit patients globally.
Investor Participation
The round saw significant interest from both existing and new investors. The involvement of prominent firms such as SR One, Medicxi, and SymBiosis underscores the confidence in FORE Biotherapeutics' potential to make substantial contributions to cancer therapy. Additionally, the participation of global investors like Samsung and Novartis Venture Fund highlights the widespread support for the company’s mission and growth prospects.
Future Outlook
With the latest funding secured, FORE Biotherapeutics is well-positioned to continue its efforts in transforming cancer treatment. The company is expected to make significant strides in the development of targeted therapies, potentially improving outcomes for patients worldwide. As it moves forward, FORE Biotherapeutics will likely remain a key player in the biotherapeutics field, leveraging its expertise and resources to drive innovation in oncology.